Recombinant protein · Protein replacement · developed by Biomarin Pharm
Cerliponase alfa is a recombinant human tripeptidyl peptidase-1 enzyme, a proenzyme taken up by CNS cells and delivered to lysosomes via the cation-independent mannose-6-phosphate receptor, where it is activated. It replaces the deficient enzyme in CLN2 disease, a neurodegenerative lysosomal storage disorder, and is studied in patients with CLN2 disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 5, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02678689 | Phase 2 | Jansky-Bielschowsky Disease | Completed | BMRN |
| NCT04476862 | N/A | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Active not recruiting | BMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Batten DiseaseCLN2 DiseaseCLN2 DisorderJansky-Bielschowsky DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.
See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMRN catalysts and pipeline →